Leman Yel

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 28

Top Topics

Hyaluronic Acid

Top Venues

Journal of clinical immunology

Annals of clinical and translational neurology

Immunotherapy advances

This page only lists publications with an associated author ORCID identifier.

Publications

Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Hirokazu Kanegane, Akifumi Endo, Satoshi Okada, Hidenori Ohnishi, Masataka Ishimura, Ryuta Nishikomori, Kohsuke Imai, Shigeaki Nonoyama, Hideki Muramatsu, Taizo Wada, Atsushi Kuga, Ko Sakamoto, Sharon Russo-Schwarzbaum, Liang-Hui Chu, Barbara McCoy, Zhaoyang Li, Leman Yel
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study. Immunotherapy advances 4 (1) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Peter Čižnár, Marion Roderick, Helen Schneiderova, Miloš Jeseňák, Gergely Kriván, Nicholas Brodszki, Stephen Jolles, Charles Atisso, Katharina Fielhauer, Shumyla Saeed-Khawaja, Barbara McCoy, Leman Yel
fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20 (1) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Stefan Roepcke, Ryan Franke, Leman Yel
Dose-exposure-efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy. Annals of clinical and translational neurology 11 (8) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Hirokazu Kanegane, Akifumi Endo, Satoshi Okada, Hidenori Ohnishi, Masataka Ishimura, Ryuta Nishikomori, Kohsuke Imai, Shigeaki Nonoyama, Hideki Muramatsu, Taizo Wada, Atsushi Kuga, Ko Sakamoto, Sharon Russo-Schwarzbaum, Liang-Hui Chu, Barbara McCoy, Zhaoyang Li, Leman Yel
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study. Immunotherapy advances 4 (1) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Stefan Roepcke, Ryan Franke, Leman Yel
Dose-exposure-efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy. Annals of clinical and translational neurology 11 (8) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Zhaoyang Li, Stefan Roepcke, Ryan Franke, Leman Yel
Dose-exposure-efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy. Annals of clinical and translational neurology 11 (8) (2024)
Zhaoyang Li, Andras Nagy, Dirk Lindner, Kimberly Duff, Enrique Garcia, Hakan Ay, Juan Carlos Rondon, Leman Yel
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants. Journal of clinical immunology 44 (7) (2024)
Pauline M Ellerbroek, Leif Gunnar Hanitsch, Torsten Witte, Vassilios Lougaris, P Martin van Hagen, Pieter van Paassen, Jie Chen, Katharina Fielhauer, Barbara McCoy, Andras Nagy, Leman Yel
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study. Immunotherapy (2024)
Zhaoyang Li, Stefan Roepcke, Ryan Franke, Leman Yel
Dose-exposure-efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy. Annals of clinical and translational neurology (2024)
Zhaoyang Li, Kristin Follman, Ed Freshwater, Frank Engler, Leman Yel
Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases. Journal of clinical immunology (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Andras Nagy, Kimberly Duff, Alexander Bauer, Fred Okonneh, Juan Carlos Rondon, Leman Yel, Zhaoyang Li
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. Journal of clinical immunology 44 (1) (2023)
Michael Borte, Stefan Raffac, Martin Hrubiško, Karina Jahnz-Rozyk, Enrique Garcia, Barbara McCoy, Shailesh Chavan, Andras Nagy, Leman Yel
Long-term safety of facilitated subcutaneous immunoglobulin treatment in pregnant women with primary immunodeficiency diseases: results from a registry study. Immunotherapy 14 (8) (2022)
Richard L Wasserman, Sudhir Gupta, Mark Stein, Christopher J Rabbat, Werner Engl, Heinz Leibl, Leman Yel
Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseases. Immunotherapy 14 (4) (2021)